Skip to content
Learn Motion
ExploreHow it worksMembership
Log in
Learn Motion

Why AI-Designed Drugs Haven't Changed Medicine Yet

1The Promise and the Puzzle2From Molecule to Medicine: The Journey a Drug Must Survive3Where AI Actually Helps in the Pipeline4The Prediction Gap: When a Good Molecule Meets a Real Body5The Long, Expensive Road of Clinical Trials6Money, Incentives, and the Business of Drug Development7Regulation, Evidence, and Trust8What Would Have to Change
The Promise and the Puzzle

Why the gap is worth explaining

3 / 3
The easy answer is that AI just does not work here, and that answer falls apart quickly. If the tools were useless, their molecules would never have interested chemists or reached human testing, and some have. So the gap has to come from somewhere else. Look at the list: behaving well in a real body, surviving years of human testing, attracting funding, convincing regulators, convincing doctors. Each of those is a separate filter, and each one removes most of what enters it. Designing a good molecule gets you past the first gate, not the rest.
0:00 / 0:00

The explanation that does not hold up

If AI were simply ineffective at drug discovery, its molecules would not be interesting to chemists and would not reach human testing at all. Some have. So the gap is not explained by the tools failing to work.

Filters a candidate must pass after design

  • Behaving well in a living body, not just in a model
  • Surviving years of testing in human volunteers and patients
  • Attracting enough funding to be developed to the end
  • Convincing regulators that the evidence supports approval
  • Convincing doctors and patients to actually use it

The question is not whether AI can design molecules. It is why designing them well has not yet changed what doctors can prescribe.

Previous3 / 3Next

Learn Motion

Generate a course. Learn it properly.

Operated by Wuhan Daoyin Technology Co., Ltd.

Contact: [email protected]
Privacy PolicyTerms of Service

© 2026 Learn Motion